Processing

Please wait...

Settings

Settings

1. WO1996005831 - METHODS OF INHIBITING ULCERATIVE MUCOSITIS

Publication Number WO/1996/005831
Publication Date 29.02.1996
International Application No. PCT/US1995/010615
International Filing Date 21.08.1995
Chapter 2 Demand Filed 15.02.1996
IPC
A61K 31/4025 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
4025not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4535 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4535containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/55 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
CPC
A61K 31/4025
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
4025not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4535
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
4535containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/55
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 1/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
Applicants
  • ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center Indianapolis, IN 46285, US (AllExceptUS)
  • CULLINAN, George, Joseph [US/US]; US (UsOnly)
Inventors
  • CULLINAN, George, Joseph; US
Agents
  • LAMMERT, Steven, R.; Barnes & Thornburg 1313 Merchants Bank Building 11 South Meridian Street Indianapolis, IN 46204, US
Priority Data
08/293,79022.08.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF INHIBITING ULCERATIVE MUCOSITIS
(FR) PROCEDES ENRAYANT LES INFLAMMATIONS ULCEREUSES DE MUQUEUSES
Abstract
(EN)
A method of inhibiting ulcerative mucositis comprising administering to a human in need thereof an effective amount of a compound having formula (I) wherein R1 and R3 are independently hydrogen, -CH3, (a) or (b), wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt or solvate thereof.
(FR)
Le procédé enrayant les inflammations ulcéreuses de muqueuses de la présente invention consiste à administrer à un être humain le nécessitant une quantité suffisante d'un composant représenté par la formule générale (I) ou de l'un de ses sels ou solvates pharmaceutiquement acceptables. Dans cette formule générale R1 et R3 sont indépendamment hydrogène, -CH3, (a) ou (b), où (b) est un phényle éventuellement substitué. R2 appartient au groupe formé par les pyrrolidine, hexaméthylèneimino et pipéridino.
Latest bibliographic data on file with the International Bureau